Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus

Nauman Wazir; Shafqat Ur Rehman

doi:10.37762/jgmds.9-3.174

Authors

Nauman Wazir East Kent University Hospitals
Shafqat Ur Rehman Naseer Teaching Hospital, Peshawar.

DOI:

https://doi.org/10.37762/jgmds.9-3.174

Keywords:

Type 2 diabetes mellitus, Empagliflozin, Total choelsterol, High-density cholesterol, Low-density cholesterol, Triglycerides

Abstract

OBJECTIVES:

To assess the effect of two doses, i.e., 10 mg and 25 mg of empagliflozin, on the lipid profile of patients with type 2 diabetes mellitus (T2DM) with suboptimal glycemic control on maximal doses of metformin and sitagliptin.

METHODOLOGY:

The study design was a randomized, open-label clinical trial. Fifty-nine adult patients of T2DM who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C > 7% <12%) were randomly allocated in 1:1 ratio to two groups, one group receiving 10 mg (Group A) and the other group receiving 25 mg of Empagliflozin (Group B) as an additional treatment. Fasting lipid profiles, including total cholesterol (TC), low-density cholesterol (LDL-C), high-density cholesterol (HDL-C) and triglycerides (TG), were taken before and 12 weeks after the addition of empagliflozin in both the groups.

RESULTS:

Total patients in group A were 31, and their mean age was 51.48±4.29 years. In group B, there were 28 patients, whose mean age was 52.39 ± 5.20 years. There was an increase in TC, LDL-C and HDL-C and a reduction of TG in both the groups after treatment with empagliflozin, but it was not statistically significant (p > 0.05).

CONCLUSION:

Both doses of Empagliflozin (10 and 25 mg) modestly elevates total cholesterol, LDL-C and HDL-C and modestly reduce triglyceride levels in T2DM patients, but the change is not statistically significant.

KEYWORDS: Empagliflozin, Type 2 diabetes mellitus, Total cholesterol, Low-density cholesterol, High-density cholesterol, Triglycerides

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Nauman Wazir, East Kent University Hospitals

Locum Consultant Physician in Diabetes and Endocrinology,
William Harvey Hospital, East Kent University Hospitals Foundation NHS Trust. UK

Shafqat Ur Rehman, Naseer Teaching Hospital, Peshawar.

Assistant Professor,
Department of Medicine, Naseer Teaching hospital, Peshawar

References

Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes & vascular disease research. 2015 Mar;12(2):78–89 DOI: https://doi.org/10.1177/1479164114561992

Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015 May;58(5):886–99 DOI: https://doi.org/10.1007/s00125-015-3525-8

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015 Nov 26;373(22):2117–28 DOI: https://doi.org/10.1056/NEJMoa1504720

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017 Aug 17;377(7):644–57 DOI: https://doi.org/10.1056/NEJMoa1611925

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology. 2019 Apr;73(15):1931–44 DOI: https://doi.org/10.1016/j.jacc.2019.01.056

Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology. 2018 Oct 25;1–9 DOI: https://doi.org/10.1080/17425255.2018.1541348

Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in therapy. 2015 Nov;32(11):1085–103. DOI: https://doi.org/10.1007/s12325-015-0255-8

Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes & Metabolism. 2014 Dec;40(6):S28–34 DOI: https://doi.org/10.1016/S1262-3636(14)72693-X

Ozcelik S, Celik M, Vural A, Aydin B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. Northern clinics of Istanbul. 2019 Dec 2;7(2):167–73 DOI: https://doi.org/10.14744/nci.2019.22697

Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, Kim G, et al. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. Clinical Therapeutics. 2016 Jun;38(6):1299–313 DOI: https://doi.org/10.1016/j.clinthera.2016.03.031

Lund SS, Sattar N, Salsali A, Crowe S, Broedl UC, Ginsberg HN. Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes. Diabetologie und Stoffwechsel [Internet]. 2016 Apr 19;11(S 01 DOI: https://doi.org/10.1055/s-0036-1580882

Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes. 2016 Apr 5;65(7):2032–8 DOI: https://doi.org/10.2337/db16-0049

Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2014 May 28;16(10):984–93 DOI: https://doi.org/10.1111/dom.12307

Zhong X, Lai D, Ye Y, Yang X, Yu B, Huang Y. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol [Internet]. 2016;72(6):655–63 DOI: https://doi.org/10.1007/s00228-016-2010-8

Wazir N, Rehman SU. Efficacy and safety of empagliflozin as add-on therapy in patients of type-2 diabetes mellitus. J Gandhara Med Dent Sci [Internet]. 2022;9(1):24–7 DOI: https://doi.org/10.37762/jgmds.9-1.173

Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PloS one. 2016 Nov 11;11(11):e0166125–e0166125 DOI: https://doi.org/10.1371/journal.pone.0166125

Zhang X-L, Zhu Q-Q, Chen Y-H, Li X-L, Chen F, Huang J-A, et al. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. Journal of the American Heart Association. 2018 Jan 20;7(2):e007165 DOI: https://doi.org/10.1161/JAHA.117.007165

Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular diabetology. 2017 Jan 13;16(1):8–8 DOI: https://doi.org/10.1186/s12933-016-0491-5

Chaplin S. ADA updates standards of diabetes care [Internet]. Wiley; 2021 DOI: https://doi.org/10.1002/pdi.0010030